UB Paderborn / Katalog / Suche / in CDI

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1051-1058

2008

Volltextzugriff (PDF)

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-07, Vol.14 (1), p.4444-4444, Article 4444

2023

Volltextzugriff (PDF)

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-08, Vol.14 (1), p.4741-4741, Article 4741

2023

Volltextzugriff (PDF)

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Journal of bone and mineral research, 2010-03, Vol.25 (3), p.463-471

2010

Volltextzugriff (PDF)

Biomarkers in oncology drug development

Molecular oncology, 2009-02, Vol.3 (1), p.24-32

2009

Volltextzugriff (PDF)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5213-5224

2021

Volltextzugriff (PDF)

Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement

British journal of cancer, 2020-02, Vol.122 (4), p.473-482

2020

Volltextzugriff (PDF)

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS13-05-PS13-05

2021

Volltextzugriff (PDF)

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

The oncologist (Dayton, Ohio), 2023-12, Vol.28 (12), p.e1248-e1258

2023

Volltextzugriff (PDF)

Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14674-e14674

2019

Volltextzugriff (PDF)

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-10

2022

Volltextzugriff (PDF)

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS3-10-GS3-10

2022

Volltextzugriff (PDF)

A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11517-11517

2020

Volltextzugriff (PDF)

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4791-4791

2018

Volltextzugriff (PDF)

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

The Journal of molecular diagnostics : JMD, 2014-05, Vol.16 (3), p.343-349

2014

Volltextzugriff (PDF)

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data

BMC cancer, 2016-08, Vol.16 (1), p.703-703, Article 703

2016

Volltextzugriff (PDF)

The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator

Toxicology and applied pharmacology, 2016-04, Vol.296, p.10-18

2016

Volltextzugriff (PDF)

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3062-3062

2019

Volltextzugriff (PDF)

A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS2614-TPS2614

2018

Volltextzugriff (PDF)

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

European journal of cancer (1990), 2007-11, Vol.43 (17), p.2523-2531

2007

Volltextzugriff (PDF)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS2603-TPS2603

2016

Volltextzugriff (PDF)

Erratum: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

Journal of bone and mineral research, 2012-06, Vol.27 (6), p.1435-1435

2012

Volltextzugriff (PDF)

Translational modelling of preclinical cardiovascular findings to patients

Journal of pharmacological and toxicological methods, 2014-11, Vol.70 (3), p.326-327

2014

Volltextzugriff (PDF)

Pancreatic circulating tumor cells: Where are they?

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e21037-e21037

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Biomarkers in oncology drug development

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Clinical development of new drug-radiotherapy combinations

Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data

The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism

A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

Erratum: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

Translational modelling of preclinical cardiovascular findings to patients

Pancreatic circulating tumor cells: Where are they?

Aktive Filter

Suchergebnisse filtern